CHD - Mergers and acquisitions

Church & Dwight Co., Inc. (NYSE:CHD) has signed a definitive agreement to acquire the TheraBreath® brand for $580 million in cash. The transaction, which is subject to regulatory approval and other customary conditions, is expected to close in the fourth quarter. TheraBreath®'s net sales for the trailing twelve months through September 30, 2021 were approximately $86 million. TheraBreath® is the #2 brand in the alcohol-free mouthwash category in the United States. International represents less than 10% of net sales. TheraBreath®'s trailing twelve months EBITDA as of September 2021 was approximately $27 million, with a 31% EBITDA margin. Once the business is fully integrated, Church & Dwig

EWING, N.J.--(BUSINESS WIRE)--Church & Dwight Co., Inc. (NYSE: CHD) has completed the acquisition of Matrixx Initiatives, Inc., the owner of the ZICAM™ brand for $530 million. The acquisition was structured as a stock purchase that the Company financed with a combination of cash and debt. Zicam is the #1 zinc supplement in the United States in the VMS (vitamins, minerals, and supplements) cough/cold shortening category. Zicam shortens the duration of a cold using zinc as the core active ingredient. “The acquisition of Zicam represents a superb addition to our existing portfolio and brings to our Company the leading brand within zinc supplements, one of the fastest-growing sub-seg